At-Home tDCS Crosses the FDA Line: What Flow's FL-100 Approval Changes for the Practice
- The FDA has granted PMA approval (P230024) for Flow Neuroscience's FL-100, the first at-home, prescription transcranial direct current stimulation (tDCS) device authorised in the United States for moderate-to-severe major depressive disorder in adults — non-treatment-refractory, as standalone or adjunct.
- Pivotal evidence comes from the fully remote, double-blind, sham-controlled Empower trial (NCT05202119, n=174 across US and UK; published in Nature Medicine, 2024): HDRS reduction of 9.41 points in the active arm versus 7.14 in sham at week 10, with remission rates 2-3x higher in active.
- Protocol is unusually demanding for a "home" device: 30-minute sessions over the left dorsolateral prefrontal cortex, 5x/week for 3 weeks, then 3x/week for 7 weeks — total 36 sessions before re-evaluation. Companion app provides clinician oversight; the device only operates under prescription.
- US launch announced for Q2 2026. In the UK the device is sold over-the-counter at £399 (or £79/month rental); the US prescription model is closer to a pharmacy DTx than to a consumer wearable, and reimbursement pathways are still undefined.
For the first time, an outpatient psychiatrist or therapist in the US can — once distribution opens this quarter — prescribe a brain-stimulation course that the patient self-administers in their living room. That changes the clinical conversation around moderate-to-severe MDD before treatment resistance is established, which is exactly the population where TMS still requires referral to a specialised clinic and where most of the patients we actually see live their depression. This is not a "lifestyle" device.
What the data actually shows
The 2.27-point HDRS gap over sham is statistically significant and clinically modest — comparable in magnitude to first-line SSRIs versus placebo in equivalent populations, and lower than reported effects from clinic-administered repetitive TMS. The remission claim of "2-3x higher" rests on the trial's chosen thresholds and should be read alongside the absolute numbers: the device produced clear separation from sham, but it did not produce miracles. The Empower trial used sustained adherence over ten weeks under remote clinical supervision — not unsupervised consumer use. Side-effect profile in the trial was dominated by mild, transient skin irritation and headache, which fits two decades of tDCS literature.
The mechanistic claim — increasing excitability of the hypoactive left DLPFC — is the same target zone as repetitive TMS for depression, but with a fundamentally different physical mechanism. tDCS is sub-threshold neuromodulation: it does not directly trigger action potentials, it shifts the probability that the underlying network will fire when the patient is engaged in a cognitive task. That is why protocol adherence and behavioural context matter more here than the operator generally controls in an at-home setting.
Where this lands in your practice
Three categories of patient become candidates the moment FL-100 reaches US distribution. First, patients with moderate MDD who decline or cannot tolerate antidepressants but who are willing to commit to a daily 30-minute protocol — this is a real population in private outpatient practice. Second, patients on SSRIs/SNRIs with partial response who are stable enough to manage adherence without the visit cadence of a TMS clinic. Third, geographically isolated patients for whom in-clinic neuromodulation has been logistically out of reach.
What it is not yet: a treatment-resistant-depression alternative (the FDA label explicitly excludes refractory cases, and TMS / ketamine / ECT remain the evidence-backed pathways), and not a self-prescribed wellness purchase. Three operational questions deserve attention before you start writing prescriptions: how reimbursement will work in 2026 (no CPT code yet for at-home tDCS supervision), how you will document the supervision relationship, and how you will assess adherence given that the app's data is reported by the device, not by the patient.
Home neuromodulation is no longer experimental — but it is also not a stand-alone fix; the supervision burden has shifted to your office, just without the chair.
The Empower trial was sponsor-supported with two enrolling centres and ten weeks of acute follow-up — there are no published long-term durability data, no head-to-head comparison with rTMS or with antidepressants, and the population was non-refractory. The 2.27-point HDRS effect over sham, while statistically significant, is modest in absolute terms.